Newsroom
-
Mammoth Biosciences Advances Lead Candidate MB-111 Toward the Clinic with the Presentation of Preclinical Durability and Safety Data at American Heart Association Scientific Sessions 2026
Business WireLearn More -
New England Biolabs® and Mammoth Biosciences® Announce Global Licensing Agreement and Commercial Launch of MB-CasFire™ to Accelerate Isothermal Amplification-Based Assay Development
PR NewswireLearn More -
Mammoth Biosciences’ MB-111 Named 2026 “Genomic Medicine of the Year” by Biotech Breakthrough Awards
Learn More -
Mammoth Biosciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Business WireLearn More -
Mammoth Biosciences is getting closer to finding out if its big bet on tiny CRISPR enzymes will pay off
Endpoints NewsLearn More -
Mammoth Biosciences to Present Preclinical Data on MB-111 at the European Society of Gene & Cell Therapy 32nd Annual Congress
Business WireLearn More -
Mammoth Biosciences Announces Nomination of MB-111 as First Development Candidate and Appoints Genetic Medicines Veteran Bob D. Brown to Board of Directors
Business WireLearn More -
Mammoth Biosciences to Present Preclinical Data on In Vivo Gene Editing of Skeletal Muscle in Non-Human Primates with an Ultracompact CRISPR System at ASGCT 2025
Business WireLearn More -